Research Paper Volume 13, Issue 7 pp 10450—10467

RIPK2 is an unfavorable prognosis marker and a potential therapeutic target in human kidney renal clear cell carcinoma

SETD2 and BAP1 genomic alterations are selectively enriched in RIPK2-high expression samples. (A) cBioPortal OncoPrint plot showing the distribution of VHL, PBRM1, CDKN2A, SETD2, BAP1, and MTOR genomic alterations rate in the TCGA KIRC dataset. (B) Bar graphs showing the percentage of TCGA KIRC samples with genomic alterations in SETD2 and BAP1 by different RIPK2 expression groups.

Figure 6. SETD2 and BAP1 genomic alterations are selectively enriched in RIPK2-high expression samples. (A) cBioPortal OncoPrint plot showing the distribution of VHL, PBRM1, CDKN2A, SETD2, BAP1, and MTOR genomic alterations rate in the TCGA KIRC dataset. (B) Bar graphs showing the percentage of TCGA KIRC samples with genomic alterations in SETD2 and BAP1 by different RIPK2 expression groups.